Early LGS-CORE Registry Data Show Only 4% of Reported Treatments Stopped All Seizures in Lennox-Gastaut Syndrome
SAN DIEGO, Oct. 20, 2026 /PRNewswire/ -- The Lennox-Gastaut Syndrome (LGS) Foundation will present the first data from its LGS Collaborative Outcomes Registry (LGS-CORE) at the 2026 NORD Rare Diseases & Orphan Products Breakthrough Summit, October 25 to 27 in Washington, DC. LGS-CORE is a...
Covered in this story
Call it yourself
No calls on $LII yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Lennox International →Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.